Story
Eli Lilly Delays FDA Filing for Next-Gen Obesity Drug Retatrutide to Q1 2027
Summary
Eli Lilly announced it will push back the regulatory filing for its promising obesity treatment, retatrutide, to the first quarter of 2027, citing the need for more manufacturing data, even as new Phase 3 trials showed significant weight loss.
Eli Lilly said Thursday it now plans to file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, a significant delay from its previous timeline targeting this year. The pharmaceutical giant stated it requires additional time to collect and verify manufacturing and quality-control data to meet regulatory standards.
Filing Delayed Despite Strong Trial Results
The revised timeline comes despite the company reporting positive outcomes from two additional Phase 3 trials. The weekly injection demonstrated substantial weight loss and improved blood sugar levels in adults with obesity and related health complications.
Key findings from the 80-week trials include:
- Adults with obesity and Type 2 diabetes lost an average of up to 20.8% of their body weight, or nearly 50 pounds.
- Adults with severe obesity and established cardiovascular disease lost an average of up to 22.6% of their body weight, or 55.8 pounds.
Common side effects were reported as diarrhea, nausea, and constipation, which the company noted are consistent with previous studies and the broader GLP-1 class of drugs.
Market Implications and Competitive Landscape
AdRetatrutide is a critical component of Lilly's strategy to dominate the lucrative weight-loss drug market, following its successful launch of Zepbound. Analysts at TD Cowen previously estimated in a January report that retatrutide could generate annual sales of $3.8 billion by 2030. The delay pushes back the potential timeline for these revenues.
The obesity drug market is intensely competitive, primarily between Eli Lilly and Danish rival Novo Nordisk, which manufactures Wegovy. The competitive pressure was highlighted earlier this week when Novo Nordisk filed a lawsuit against Lilly, alleging false advertising related to the performance of its weight-loss medications.
A Differentiated 'Triple-Agonist' Drug
Unlike existing treatments, retatrutide is a 'triple-agonist' that targets three distinct hormones involved in metabolism: GLP-1, GIP, and glucagon. This mechanism differs from Lilly's own Zepbound (tirzepatide), which targets GLP-1 and GIP, and Novo Nordisk's Wegovy (semaglutide), which mimics only GLP-1.
Kenneth Custer, president of Lilly Cardiometabolic Health, stated that the company believes it has the necessary information to eventually seek global approval for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea.
Read next
More on Stocks
DensityAI in Talks for Funding at $10 Billion Valuation, Report Says
The AI chip startup is reportedly in advanced discussions to raise hundreds of millions, a move bolstered by a conditional chip-purchasing agreement with Amazon Web Services.
SoftBank Stock Slides as Investors Scrutinize Cost of Record Bond Sale
Shares of the Japanese tech conglomerate fell after its record $11.1 billion bond sale locked in high financing costs, while reports of trouble at a major data center project raised concerns about its AI strategy.
SoftBank Shares Dip as Oracle Data Center Warning Stokes AI Project Fears
Shares of the Japanese investment giant fell after Oracle issued a notice over potential delays at a key New Mexico data center, raising investor concerns about the financing and execution of large-scale AI infrastructure.
Asian Stocks Fall as Surging Bond Yields Overshadow U.S.-China Trade Truce
Most Asian markets declined as a global bond selloff sent U.S. Treasury yields to multi-decade highs, weighing on risk appetite. A two-month extension of the U.S.-China trade truce failed to provide significant support to investor sentiment.